<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170563">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876148</url>
  </required_header>
  <id_info>
    <org_study_id>LAM Allo SCT</org_study_id>
    <nct_id>NCT00876148</nct_id>
  </id_info>
  <brief_title>Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting</brief_title>
  <official_title>Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients
      undergoing allografting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <condition>Hepatitis B Virus</condition>
  <condition>Allograft</condition>
  <condition>Hematological Malignancies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort of patients undergoing allografting for hematological malignancies
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing an allograft for hematological malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda ospedaliera S Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>April 3, 2009</lastchanged_date>
  <firstreceived_date>April 3, 2009</firstreceived_date>
  <keyword>Incidence of hepatitis B after allografting</keyword>
  <keyword>Risk of hepatitis B reactivation</keyword>
  <keyword>Lamivudine prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
